SENSEX NIFTY
81481.86 24821.1
143.91 (0.18%)
140.20 (0.57%)
 

NOTICES


Heading View
  SEBI Circular No. CIR/MRD/DP/01/2014 Dated 7th January, 2014   Click here
  SEBI Circular No. SEBI/HO/MIRSD/MIRSD2/CIR/P/2016/95, Dated 26th September, 2016.   Click here
DETACH
Increase
Minus
Hot Pursuit Back
Indegene launches NEXT Medical Writing Automation
(12 Jul 2025, 11:08)
NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI).

Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegene's decades of domain knowledge with the power of its AI engine, Cortex.

Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, 'With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence.

We see this platform as more than automation'it's about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.'

Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecycle'more effectively, efficiently, and in a modern, technology-driven manner.

The company's consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24.

The scrip declined 1.02% to settle at Rs 564.35 on the BSE.

Powered by Capital Market - Live News

 
Attention Investors: No need to issue cheques by investors while subscribing to IPO. just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account. | Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.' "
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Dear Clients: We are here with requesting you to submit your separate e-mail id to receive communications/reports, by submitting account modification form in this regards or if you have registered your family member e-mail id with us, please submit declaration in this regards. Further, if you have not registered e-mail id/mobile number with us, please register it by submitting account modification form which facilitates you to receive all the data/reports electronically. If you require any clarification, please feel free to call Mr. Hemant Shah on 9004603818 or email us at kyc@swcapital.in
Feedback | Back Office | Downloads | KYC | Disclaimer | Privacy Policy | Investor Grievances | Communique | Tariff Structure |
SCORES| Opening A Account| Filing A Complaints|
Copyright © 2011 -SW Capital Pvt Ltd. All rights reserved. Designed, developed & powered by C-MOTS Infotech (ISO 9001:2015 certified)